AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36853800 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 28
Study 36853800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 36854054 — intervention group
Group type: EXPERIMENTAL
Intervention: Stool CMV-PCR
Number of subjects: 117
Study 36854054 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma CMV-PCR
Number of subjects: 117
Study 36854054 — intervention group
Group type: EXPERIMENTAL
Intervention: Either positive plasma or positive stool CMV-PCR
Number of subjects: 117
Study 36854054 — intervention group
Group type: EXPERIMENTAL
Intervention: Both positive stool and plasma CMV-PCR
Number of subjects: 117
Study 36854054 — intervention group
Group type: EXPERIMENTAL
Intervention: Stool CMV-PCR and Plasma CMV-PCR correlation
Number of subjects: 117
Study 36854054 — intervention group
Group type: EXPERIMENTAL
Intervention: Stool CMV-PCR correlation with cytomegalic cell count
Number of subjects: 117
Study 36854054 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma CMV-PCR correlation with cytomegalic cell count
Number of subjects: 117
Study 36854054 — intervention group
Group type: COMPARATOR
Intervention: Volunteers
Number of subjects: 117
Study 36854071 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinutuximab beta (DB) plus subcutaneous interleukin-2 (scIL2) after haplo-SCT
Number of subjects: 68
Study 36854097 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel tests including blood, urine, and stool collection for TB diagnosis
Number of subjects: 1000
Study 36854097 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard assessments including TB signs and symptoms, TB history, radiography, tuberculin skin test, HIV testing, and spirometry
Number of subjects: 1000
Study 36854097 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference standard testing (culture, Xpert Ultra) using respiratory samples (sputum, gastric aspirate, nasopharyngeal aspirate)
Number of subjects: 1000
Study 36854112 — intervention group
Group type: EXPERIMENTAL
Intervention: Concussion-related return to the ED within 3 months
Number of subjects: 632
Study 36854112 — intervention group
Group type: EXPERIMENTAL
Intervention: Concussion-related return to the ED within 14 days
Number of subjects: 632
Study 36854112 — intervention group
Group type: EXPERIMENTAL
Intervention: History of migraines
Number of subjects: 632
Study 36854112 — intervention group
Group type: EXPERIMENTAL
Intervention: Headache as a symptom on revisit
Number of subjects: 632
Study 36854112 — intervention group
Group type: EXPERIMENTAL
Intervention: Return rate by gender and age
Number of subjects: 632
Study 36854112 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk scores in prognostication
Number of subjects: 632
Study 36854366 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intent
Number of subjects: 2406
Study 36854366 — intervention group
Group type: COMPARATOR
Intervention: Already Vaccinated
Number of subjects: 2406
Study 36854456 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived workplace support (assessed via self-reported level on a single-item Likert scale)
Number of subjects: 0
Study 36854456 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in perceived workplace support
Number of subjects: 0
Study 36854566 — intervention group
Group type: EXPERIMENTAL
Intervention: Burosumab
Number of subjects: 31
Study 36854570 — intervention group
Group type: EXPERIMENTAL
Intervention: Bispecific antibody (bsAb)-KN046
Number of subjects: 18
Study 36854583 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioural therapy for 12 weeks
Number of subjects: 174
Study 36854583 — intervention group
Group type: COMPARATOR
Intervention: Digital self-care intervention for 12 weeks
Number of subjects: 174
Study 36854583 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis at 1-year follow-up
Number of subjects: 174
Study 36854583 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary outcome measure (Patient-oriented Eczema Measure)
Number of subjects: 174
Study 36854592 — intervention group
Group type: EXPERIMENTAL
Intervention: Viborg Screening Programme (VISP)
Number of subjects: 1100
Study 36854592 — intervention group
Group type: COMPARATOR
Intervention: Control group (surrounding municipalities)
Number of subjects: 1100
Study 36854596 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical mask
Number of subjects: 130
Study 36854596 — intervention group
Group type: COMPARATOR
Intervention: No surgical mask
Number of subjects: 130
Study 36854601 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive protocol for non-resuscitation fluids
Number of subjects: 0
Study 36854601 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 36854601 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 0
Study 36854604 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib combined with GEMOX chemotherapy (gemcitabine and oxaliplatin)
Number of subjects: 0
Study 36854798 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-oxide-impregnated polyvinylidene fluoride (PVDF) mesh
Number of subjects: 20
Study 36854863 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel methodology for direct co-registration of autoradiographs and histopathology
Number of subjects: 5
Study 36854893 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus
Number of subjects: 3420
Study 36854893 — intervention group
Group type: COMPARATOR
Intervention: No diabetes mellitus
Number of subjects: 3420
Study 36854916 — intervention group
Group type: EXPERIMENTAL
Intervention: Identified biomarkers for SIDD (n=13)
Number of subjects: 7017
Study 36854916 — intervention group
Group type: EXPERIMENTAL
Intervention: Identified biomarkers for SIRD (n=2)
Number of subjects: 7017
Study 36854916 — intervention group
Group type: EXPERIMENTAL
Intervention: Identified biomarkers for MOD (n=7)
Number of subjects: 7017
Study 36854916 — intervention group
Group type: EXPERIMENTAL
Intervention: Identified biomarkers for MARD (n=11)
Number of subjects: 7017
Study 36855020 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg
Number of subjects: 855
Study 36855020 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg
Number of subjects: 855
Study 36855089 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 120
Study 36855089 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine-based analgesia
Number of subjects: 120
Study 36855089 — intervention group
Group type: EXPERIMENTAL
Intervention: Piritramide-based analgesia
Number of subjects: 120
Study 36855089 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 120
Study 36855099 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafolecimab 150 mg Q2W
Number of subjects: 149
Study 36855099 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafolecimab 450 mg Q4W
Number of subjects: 149
Study 36855099 — intervention group
Group type: COMPARATOR
Intervention: Placebo Q2W
Number of subjects: 149
Study 36855099 — intervention group
Group type: COMPARATOR
Intervention: Placebo Q4W
Number of subjects: 149
Study 36855099 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafolecimab (both doses)
Number of subjects: 149
Study 36855109 — intervention group
Group type: EXPERIMENTAL
Intervention: 300,000 IU cholecalciferol followed by 1400 IU cholecalciferol + 500 mg of calcium daily (n = 151)
Number of subjects: 307
Study 36855109 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 156)
Number of subjects: 307
Study 36855109 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 307
Study 36855155 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 280
Study 36855155 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 280
Study 36855160 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous ketamine infusions
Number of subjects: 56
Study 36855160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 36855169 — intervention group
Group type: EXPERIMENTAL
Intervention: Wangbi granule 12.0 g, three times a day for 12 weeks
Number of subjects: 340
Study 36855169 — intervention group
Group type: COMPARATOR
Intervention: Wangbi placebo 12.0 g, three times a day for 12 weeks
Number of subjects: 340
Study 36855177 — intervention group
Group type: EXPERIMENTAL
Intervention: estradiol treatment for 3 weeks
Number of subjects: 100
Study 36855177 — intervention group
Group type: COMPARATOR
Intervention: placebo treatment for 3 weeks
Number of subjects: 100
Study 36855194 — intervention group
Group type: EXPERIMENTAL
Intervention: HOLA health promotion intervention (community health worker-led, multicomponent intervention including social and physical activation session, group walk for 45 min, 3×/week for 16 weeks)
Number of subjects: 18
Study 36855202 — intervention group
Group type: EXPERIMENTAL
Intervention: Eustachian tube dilation using an endovascular balloon
Number of subjects: 12
Study 36855211 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-step StreamLight® TE-PRK using EX500 excimer laser (Alcon Laboratories, USA)
Number of subjects: 30
Study 36855214 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based dance intervention (8-week, 3 times/week)
Number of subjects: 64
Study 36855214 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 64
Study 36855328 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial-based risk communication intervention
Number of subjects: 14
Study 36855334 — intervention group
Group type: EXPERIMENTAL
Intervention: Fabric-Based Wireless Electroceutical Dressing
Number of subjects: 0
Study 36855334 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-Care Treatment
Number of subjects: 0
Study 36855737 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal Intubation
Number of subjects: 142
Study 36855931 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild group (DS < 50%)
Number of subjects: 480
Study 36855931 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate group (DS 50%-70%)
Number of subjects: 480
Study 36855931 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe group (DS > 70%)
Number of subjects: 480
Study 36855931 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 480
Study 36855931 — intervention group
Group type: EXPERIMENTAL
Intervention: Angio-FFR ≤ 0.8
Number of subjects: 480
Study 36856064 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral high-frequency noninvasive peroneal nerve stimulation (NPNS)
Number of subjects: 20
Study 36856064 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 20
Study 36856104 — intervention group
Group type: EXPERIMENTAL
Intervention: Kabat Motor Control Re-education
Number of subjects: 30
Study 36856104 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy selected designed program (Control)
Number of subjects: 30
Study 36856122 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral intake of fermented milk
Number of subjects: 0
Study 36856135 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothetical polygenic risk scores for alcohol use disorder
Number of subjects: 325
Study 36856258 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper version of the Integrated Palliative Care Outcome Scale (IPOS)
Number of subjects: 50
Study 36856258 — intervention group
Group type: COMPARATOR
Intervention: Electronic version of the Integrated Palliative Care Outcome Scale (eIPOS)
Number of subjects: 50
Study 36856280 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrupled semitendinosus tendon (ST) graft
Number of subjects: 162
Study 36856280 — intervention group
Group type: COMPARATOR
Intervention: Doubled semitendinosus and gracilis tendon (ST/G) graft
Number of subjects: 162
Study 36856456 — intervention group
Group type: COMPARATOR
Intervention: Novel Dietary Supplement
Number of subjects: 0
Study 36856614 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 12.5 mg once daily
Number of subjects: 416
Study 36856614 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25 mg once daily
Number of subjects: 416
Study 36856614 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 50 mg once daily
Number of subjects: 416
Study 36856614 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily
Number of subjects: 416
Study 36856617 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant-adjuvant pembrolizumab (3 doses before surgery and 15 doses after surgery)
Number of subjects: 313
Study 36856617 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant-only pembrolizumab (200 mg intravenously every 3 weeks for a total of 18 doses)
Number of subjects: 313
Study 36856617 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant-adjuvant pembrolizumab
Number of subjects: 313
Study 36856617 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant-only pembrolizumab
Number of subjects: 313
Study 36856701 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (10-20 mg/day)
Number of subjects: 100
Study 36856701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 36856733 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide (first-line chemotherapy)
Number of subjects: 0
Study 36856733 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (second-line treatment)
Number of subjects: 0
Study 36856733 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 0
Study 36856733 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitors and everolimus
Number of subjects: 0
Study 36856733 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide receptor radionuclide therapy
Number of subjects: 0
Study 36856748 — intervention group
Group type: EXPERIMENTAL
Intervention: No drainage after elective day-case laparoscopic cholecystectomy
Number of subjects: 200
Study 36856748 — intervention group
Group type: COMPARATOR
Intervention: Drainage after elective day-case laparoscopic cholecystectomy
Number of subjects: 200
Study 36856835 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic lavage
Number of subjects: 209
Study 36856835 — intervention group
Group type: COMPARATOR
Intervention: Resection
Number of subjects: 209
Study 36856848 — intervention group
Group type: EXPERIMENTAL
Intervention: ProTaper Universal Retreatment (PTUR)
Number of subjects: 75
Study 36856848 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciproc Blue (RB)
Number of subjects: 75
Study 36856848 — intervention group
Group type: EXPERIMENTAL
Intervention: D-Race (DR) + XP-Endo Finisher R (XPFR)
Number of subjects: 75
Study 36856866 — intervention group
Group type: EXPERIMENTAL
Intervention: APOE-ε4 carriers with positive Aβ PET VR in temporal areas (n=19, 9.81%)
Number of subjects: 352
Study 36856866 — intervention group
Group type: EXPERIMENTAL
Intervention: APOE-ε4 carriers with positive Aβ PET VR in the striatum (n=8, 4.14%)
Number of subjects: 352
Study 36856866 — intervention group
Group type: EXPERIMENTAL
Intervention: APOE-ε4 carriers with positive Aβ PET VR in temporal and parietal regions, and in the striatum
Number of subjects: 352
Study 36856866 — intervention group
Group type: EXPERIMENTAL
Intervention: APOE-ε4 carriers (general)
Number of subjects: 352
Study 36856877 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1 treatment
Number of subjects: 22
Study 36856978 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cyclosporine-A (CsA) 0.1% cationic emulsion (Ikervis) instilled once daily to both eyes from 3-5 weeks pre-HSCT to 12 months post-HSCT
Number of subjects: 19
Study 36856978 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cyclosporine-A (CsA) 0.1% cationic emulsion (Ikervis)
Number of subjects: 19
Study 36857035 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 14565
Study 36857035 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14565
Study 36857053 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive BP treatment (SBP target <120 mm Hg)
Number of subjects: 670
Study 36857058 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous fat transfer (AFT)
Number of subjects: 193
Study 36857058 — intervention group
Group type: COMPARATOR
Intervention: Implant-based reconstruction (IBR)
Number of subjects: 193
Study 36857103 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at diagnosis <6 years
Number of subjects: 709
Study 36857103 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at diagnosis <2 years
Number of subjects: 709
Study 36857103 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior hypothalamic involvement and hypothalamic lesion (HL)
Number of subjects: 709
Study 36857103 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at diagnosis
Number of subjects: 709
Study 36857318 — intervention group
Group type: EXPERIMENTAL
Intervention: 4S-AF scheme
Number of subjects: 341
Study 36857318 — intervention group
Group type: EXPERIMENTAL
Intervention: 3S-AF scheme (excluding symptoms domain)
Number of subjects: 341
Study 36857330 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital meditation (MED)
Number of subjects: 161
Study 36857330 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital meditation + healthy eating (MED+HE)
Number of subjects: 161
Study 36857330 — intervention group
Group type: COMPARATOR
Intervention: Active control (HE)
Number of subjects: 161
Study 36857330 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (WL)
Number of subjects: 161
Study 36857330 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital meditation (MED) for those high in binge eating
Number of subjects: 161
Study 36857330 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital meditation + healthy eating (MED+HE) for those high in binge eating
Number of subjects: 161
Study 36857339 — intervention group
Group type: EXPERIMENTAL
Intervention: RELiZORB enzyme cartridge used daily with enteral nutrition (EN) for 90 days
Number of subjects: 0
Study 36857393 — intervention group
Group type: EXPERIMENTAL
Intervention: ATG 4.5 mg/kg
Number of subjects: 36
Study 36857393 — intervention group
Group type: COMPARATOR
Intervention: ATG 6.0 mg/kg
Number of subjects: 36
Study 36857477 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 15 mg
Number of subjects: 117
Study 36857477 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 1 mg
Number of subjects: 117
Study 36857477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 36857519 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute myocardial infarction (AMI) patients
Number of subjects: 2705
Study 36857519 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined phenotype of 'MA ≥ 68 mm' and 'LY30 < 0.2%' in AMI patients
Number of subjects: 2705
Study 36857519 — intervention group
Group type: COMPARATOR
Intervention: Non-AMI patients
Number of subjects: 2705
Study 36857596 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 2045
Study 36857596 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin + Aspirin
Number of subjects: 2045
Study 36857596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2045
Study 36857740 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacto-ovo-vegetarians (LOV)
Number of subjects: 64
Study 36857740 — intervention group
Group type: COMPARATOR
Intervention: Non-vegetarians (NV)
Number of subjects: 64
Study 36857956 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapidly cleaved saccharose (SAC)
Number of subjects: 0
Study 36857956 — intervention group
Group type: EXPERIMENTAL
Intervention: Slowly cleaved isomaltulose (ISO)
Number of subjects: 0
Study 36857956 — intervention group
Group type: EXPERIMENTAL
Intervention: Test meals containing saccharose or isomaltulose with milk protein
Number of subjects: 0
Study 36857956 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein
Number of subjects: 0
Study 36857956 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein
Number of subjects: 0
Study 36857956 — intervention group
Group type: COMPARATOR
Intervention: Endogenous incretins
Number of subjects: 0
Study 36857962 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 days of bed rest
Number of subjects: 20
Study 36857997 — intervention group
Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 5500
Study 36858257 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine infusion at 0.03 mcg/kg/min
Number of subjects: 271
Study 36858257 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine infusion at 0.02 mcg/kg/min
Number of subjects: 271
Study 36858257 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine infusion at 0.01 mcg/kg/min
Number of subjects: 271
Study 36858257 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine infusion (all doses)
Number of subjects: 271
Study 36858265 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment for 8 weeks
Number of subjects: 159
Study 36858265 — intervention group
Group type: COMPARATOR
Intervention: Normal controls (NCs)
Number of subjects: 159
Study 36858270 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 42
Study 36858602 — intervention group
Group type: EXPERIMENTAL
Intervention: CADScorSystem (ultrasensitive microphone for diastolic heart sound analysis)
Number of subjects: 167
Study 36858602 — intervention group
Group type: COMPARATOR
Intervention: Serial high-sensitive troponin T measurements
Number of subjects: 167
Study 36858662 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-expanding transcatheter heart valves (THVs)
Number of subjects: 723
Study 36858662 — intervention group
Group type: COMPARATOR
Intervention: Balloon-expandable transcatheter heart valves (THVs)
Number of subjects: 723
Study 36858721 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib (20 mg per day orally in 21-day cycles) plus pembrolizumab (200 mg intravenously every 21 days)
Number of subjects: 1069
Study 36858721 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib (50 mg per day orally, 4 weeks on and 2 weeks off)
Number of subjects: 1069
Study 36858722 — intervention group
Group type: EXPERIMENTAL
Intervention: OEPA (vincristine 1·5 mg/m², etoposide, prednisone, and doxorubicin) without radiotherapy
Number of subjects: 713
Study 36858722 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 713
Study 36858723 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant paclitaxel and trastuzumab
Number of subjects: 406
Study 36858723 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2DX risk score
Number of subjects: 406